Agentix Corp.

What they do

Agentix Corp. was incorporated in Nevada on April 18, 2013, and changed its name from FairWind Energy, Inc. effective June 17, 2019, to focus on pharmaceutical treatments in the metabolic disease space. In June 2020, it acquired GSL Healthcare, Inc. via a share exchange; GSL Healthcare became a wholly-owned subsidiary and its two former shareholders hold approximately 88.0% of the company. In September 2022, it formed Agentix Australia Pty Ltd to conduct development activities and access a 43.5% Australian tax rebate for biotechnology and pharmaceutical development. The company is developing two key assets designed not to cross the blood-brain barrier, targeting metabolic syndrome.

Revenue drivers

• Pharmaceutical development stage — No revenue has been recorded in recent periods; the company reported $0 revenue for fiscal years 2026 and 2025, and $0 revenue for the three months ended June 30, 2026 and 2025.
• Historical composite products — The company previously focused on designing, engineering and manufacturing composite products for the oil and gas industry, but this business was superseded by the GSL Healthcare share exchange in June 2020.
• Australian R&D tax rebate — Agentix Australia Pty Ltd was established to participate in an Australian program that reimburses 43.5% of expenses for biotechnology and/or pharmaceutical development activities conducted in Australia.

Recent performance

For the fiscal year ended March 31, 2026, Agentix recorded no revenues, professional fees of $252,036, research and development expenses of $125,079, and general and administrative expenses of $68,072. The company reported a net loss of $485,636 for fiscal 2026, compared to a net loss of $567,048 for fiscal 2025. Operating cash used was $108,529 in fiscal 2026 versus $125,078 in fiscal 2025. For the three months ended June 30, 2026, the company reported a net loss of $117,674, compared to a net loss of $185,824 for the same period in 2025, with no revenue in either period. As of June 30, 2026, the company had total assets of $38, total liabilities of approximately $3.7 million, and shareholders' equity of approximately negative $3.7 million.

Strategy

Agentix plans to focus on developing and commercializing novel therapeutics for metabolic disease, specifically two peripherally-restricted assets that do not cross the blood-brain barrier. The company envisions developing new chemical entities to initial clinical efficacy stages and then partnering with larger biopharma players for pivotal commercialization stages. It formed an Australian subsidiary to conduct development activities and participate in a 43.5% tax rebate program. Management states that additional funding will likely come from equity or debt financing, and that without such financing, the business will likely fail. The company has no off-balance sheet arrangements.

Risks

• Going concern — The company has an accumulated deficit of $7,124,838 as of June 30, 2026, no revenue, and negative operating cash flow, raising substantial doubt about its ability to continue as a going concern.
• No revenue — Agentix has not generated meaningful revenues from its business and recorded no revenues during the years ended March 31, 2026 and 2025, or during the three months ended June 30, 2026 and 2025.
• Liquidity and capital needs — At June 30, 2026, the company had cash of $38, negative working capital of $3,713,793, and total current liabilities of $3,713,831.
• Debt maturity and related-party obligations — The company owes vendors and related parties $3,596,282 as of March 31, 2026, and the two Mezzanine Secured Notes with Gray's Peak Private Credit LLC have short-term debt maturities.

Outlook

Management states that the company needs to raise funds to complete its plan of operation and fund ongoing operational expenses for the next 12 months. Additional funding will likely come from equity financing from the sale of common stock or debt financing, which may dilute existing shareholders or have unfavorable terms. The company cannot provide assurance that it will be able to raise sufficient funding, and in the absence of such financing, its business will likely fail. Management says it is attempting to commence operations and generate sufficient revenue, but its cash position is not sufficient to support daily operations.